August 2015 August 2015
New Product - Otezla
Otezla (apremilast) an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. Otezla is indicated for the treatment of signs and symptoms of active psoriatic arthritis in adult patients and also for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. It is contraindicated during pregnancy and in nursing women. Otezla is available as a two week titration pack (containing 4 x 10 mg tablets, 4 x 20 mg tablets and 5 x 30 mg tablets for the first week of dose titration and 14 x 30 mg tablets for the second week). It is also available as a four week pack (56 x 30 mg tablets).
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au